AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
trimebutine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2748 | 39133-31-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 5 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK | 45 | |||
| kinase-selectivity-class | AXL,DDR1,EPHB4,ERBB2,GRK2,PDK4,SIK2 | 7 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyponatraemia | 122.47 | 29.09 | 71 | 3351 | 133467 | 90491558 |
| Necrosis ischaemic | 105.64 | 29.09 | 20 | 3402 | 975 | 90624050 |
| Pneumonia streptococcal | 90.36 | 29.09 | 20 | 3402 | 2121 | 90622904 |
| Beta haemolytic streptococcal infection | 87.12 | 29.09 | 20 | 3402 | 2499 | 90622526 |
| Colitis microscopic | 81.70 | 29.09 | 26 | 3396 | 11133 | 90613892 |
| Fall | 77.76 | 29.09 | 93 | 3329 | 481717 | 90143308 |
| Hypokalaemia | 75.57 | 29.09 | 52 | 3370 | 131064 | 90493961 |
| Coma | 70.15 | 29.09 | 40 | 3382 | 72592 | 90552433 |
| Schizencephaly | 70.01 | 29.09 | 12 | 3410 | 331 | 90624694 |
| Cerebral haemorrhage foetal | 69.84 | 29.09 | 12 | 3410 | 336 | 90624689 |
| Acute kidney injury | 69.05 | 29.09 | 72 | 3350 | 320315 | 90304710 |
| Cardio-respiratory arrest | 67.02 | 29.09 | 37 | 3385 | 63103 | 90561922 |
| Septic shock | 59.65 | 29.09 | 38 | 3384 | 84122 | 90540903 |
| Interstitial lung disease | 57.91 | 29.09 | 36 | 3386 | 76369 | 90548656 |
| Hypophosphataemia | 55.70 | 29.09 | 21 | 3401 | 14833 | 90610192 |
| Drug reaction with eosinophilia and systemic symptoms | 53.61 | 29.09 | 28 | 3394 | 42730 | 90582295 |
| Poisoning deliberate | 53.57 | 29.09 | 21 | 3401 | 16465 | 90608560 |
| Rash maculo-papular | 46.21 | 29.09 | 25 | 3397 | 40908 | 90584117 |
| Traumatic haematoma | 45.07 | 29.09 | 11 | 3411 | 1784 | 90623241 |
| Hypomagnesaemia | 40.91 | 29.09 | 22 | 3400 | 35566 | 90589459 |
| Colitis | 40.85 | 29.09 | 28 | 3394 | 69914 | 90555111 |
| Hypocalcaemia | 39.98 | 29.09 | 23 | 3399 | 42345 | 90582680 |
| Toxic skin eruption | 37.28 | 29.09 | 16 | 3406 | 15758 | 90609267 |
| Granulomatous liver disease | 35.31 | 29.09 | 8 | 3414 | 941 | 90624084 |
| Bradycardia | 34.12 | 29.09 | 27 | 3395 | 83820 | 90541205 |
| Febrile bone marrow aplasia | 33.74 | 29.09 | 13 | 3409 | 9725 | 90615300 |
| Transverse sinus thrombosis | 32.97 | 29.09 | 7 | 3415 | 610 | 90624415 |
| Respiratory distress | 31.13 | 29.09 | 19 | 3403 | 38927 | 90586098 |
| Superior sagittal sinus thrombosis | 31.10 | 29.09 | 7 | 3415 | 799 | 90624226 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Infection parasitic | 50.27 | 25.65 | 10 | 2467 | 407 | 42618451 |
| Gastrointestinal bacterial infection | 45.24 | 25.65 | 10 | 2467 | 681 | 42618177 |
| Encephalopathy | 43.30 | 25.65 | 28 | 2449 | 41305 | 42577553 |
| Wrong patient received product | 32.87 | 25.65 | 11 | 2466 | 3572 | 42615286 |
| Hepatic cytolysis | 32.65 | 25.65 | 20 | 2457 | 26824 | 42592034 |
| Drug effect less than expected | 28.22 | 25.65 | 10 | 2467 | 3847 | 42615011 |
| Acute kidney injury | 27.99 | 25.65 | 64 | 2413 | 367273 | 42251585 |
| Tumour necrosis | 27.53 | 25.65 | 8 | 2469 | 1636 | 42617222 |
| Mydriasis | 26.44 | 25.65 | 12 | 2465 | 8758 | 42610100 |
| Faeces soft | 25.87 | 25.65 | 10 | 2467 | 4902 | 42613956 |
| Respiratory gas exchange disorder | 25.77 | 25.65 | 6 | 2471 | 515 | 42618343 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyponatraemia | 96.41 | 24.25 | 85 | 5804 | 217568 | 110365842 |
| Necrosis ischaemic | 92.54 | 24.25 | 20 | 5869 | 1339 | 110582071 |
| Acute kidney injury | 86.52 | 24.25 | 135 | 5754 | 635295 | 109948115 |
| Coma | 79.72 | 24.25 | 59 | 5830 | 117810 | 110465600 |
| Beta haemolytic streptococcal infection | 76.98 | 24.25 | 20 | 5869 | 2951 | 110580459 |
| Pneumonia streptococcal | 73.80 | 24.25 | 20 | 5869 | 3469 | 110579941 |
| Hypokalaemia | 68.52 | 24.25 | 65 | 5824 | 182383 | 110401027 |
| Colitis microscopic | 68.26 | 24.25 | 26 | 5863 | 13368 | 110570042 |
| Cardio-respiratory arrest | 58.87 | 24.25 | 49 | 5840 | 115787 | 110467623 |
| Encephalopathy | 55.73 | 24.25 | 41 | 5848 | 81014 | 110502396 |
| Fall | 53.11 | 24.25 | 106 | 5783 | 603376 | 109980034 |
| Rash maculo-papular | 52.06 | 24.25 | 38 | 5851 | 74184 | 110509226 |
| Anal fissure | 49.70 | 24.25 | 19 | 5870 | 9862 | 110573548 |
| Hypomagnesaemia | 49.49 | 24.25 | 34 | 5855 | 60336 | 110523074 |
| Hypocalcaemia | 49.35 | 24.25 | 35 | 5854 | 65331 | 110518079 |
| Interstitial lung disease | 49.18 | 24.25 | 48 | 5841 | 139286 | 110444124 |
| Poisoning deliberate | 45.61 | 24.25 | 24 | 5865 | 26307 | 110557103 |
| Hepatic cytolysis | 45.11 | 24.25 | 31 | 5858 | 55022 | 110528388 |
| Infection parasitic | 43.53 | 24.25 | 10 | 5879 | 884 | 110582526 |
| Septic shock | 42.51 | 24.25 | 47 | 5842 | 157481 | 110425929 |
| Hypophosphataemia | 40.42 | 24.25 | 24 | 5865 | 33158 | 110550252 |
| Drug reaction with eosinophilia and systemic symptoms | 40.19 | 24.25 | 34 | 5855 | 82061 | 110501349 |
| Febrile bone marrow aplasia | 39.28 | 24.25 | 19 | 5870 | 17446 | 110565964 |
| Toxic skin eruption | 39.10 | 24.25 | 22 | 5867 | 27493 | 110555917 |
| Gastrointestinal bacterial infection | 38.95 | 24.25 | 10 | 5879 | 1408 | 110582002 |
| Traumatic haematoma | 38.05 | 24.25 | 11 | 5878 | 2410 | 110581000 |
| Inappropriate antidiuretic hormone secretion | 37.41 | 24.25 | 23 | 5866 | 33828 | 110549582 |
| Enteritis | 34.71 | 24.25 | 18 | 5871 | 19138 | 110564272 |
| Transverse sinus thrombosis | 28.95 | 24.25 | 7 | 5882 | 771 | 110582639 |
| Cholestasis | 28.09 | 24.25 | 25 | 5864 | 64493 | 110518917 |
| Wrong patient received product | 27.12 | 24.25 | 11 | 5878 | 6663 | 110576747 |
| Arteriospasm coronary | 27.01 | 24.25 | 12 | 5877 | 9088 | 110574322 |
| Drug ineffective | 26.86 | 24.25 | 25 | 5864 | 1520515 | 109062895 |
| Superior sagittal sinus thrombosis | 26.22 | 24.25 | 7 | 5882 | 1146 | 110582264 |
| Tumour necrosis | 25.11 | 24.25 | 8 | 5881 | 2428 | 110580982 |
| Miosis | 24.45 | 24.25 | 15 | 5874 | 21968 | 110561442 |
| Eosinophilia | 24.33 | 24.25 | 22 | 5867 | 57914 | 110525496 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A03AA05 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS Synthetic anticholinergics, esters with tertiary amino group |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D010276 | Parasympatholytics |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
Related Drugs by ATC class:
A03AA Synthetic anticholinergics, esters with tertiary amino group 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.6 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D01500 | KEGG_DRUG |
| 34140-59-5 | SECONDARY_CAS_RN |
| C0041023 | UMLSCUI |
| CHEBI:748711 | CHEBI |
| CHEMBL190044 | ChEMBL_ID |
| DB09089 | DRUGBANK_ID |
| D014287 | MESH_DESCRIPTOR_UI |
| 5573 | PUBCHEM_CID |
| 2773 | INN_ID |
| QZ1OJ92E5R | UNII |
| 10819 | RXNORM |
| 003502 | NDDF |
| 003503 | NDDF |
| 698184001 | SNOMEDCT_US |
| 703719009 | SNOMEDCT_US |
| QZ1OJ92E5R | INXIGHT DRUGS |
Pharmaceutical products:
None